Efficacy and Safety of Low‐Frequency Daratumumab Regimen in Systemic Light‐Chain Amyloidosis

ABSTRACT In recent years, daratumumab has been increasingly applied in the treatment of systemic light‐chain (AL) amyloidosis, significantly improving the prognosis of patients. Currently, the internationally recognized daratumumab treatment regimen comes from the ANDROMEDA trial. Given the low tumo...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Jintao Lin, Hui Yan, Xinyi Meng, Jingsong He, Jinuo Wang, Xiaoyan Han, Jian Shen, Qiu Fang, Li Huang, Gaofeng Zheng, Wenjun Wu, Yi Zhao, Yi Li, Li Yang, Xing Guo, Jing Chen, Haimeng Yan, Zhen Cai, Donghua He
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Wiley 2026-07-01
Cyfres:	Cancer Medicine
Pynciau:	AL amyloidosis CD38 daratumumab Low‐frequency therapy plasma‐cell
Mynediad Ar-lein:	https://doi.org/10.1002/cam4.72103
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!